National Institute of Allergy and Infectious Diseases (NIAID): all 2,445 studies

Page 8 of 25. Open to participants first (182), then studies with results posted, then the rest; newest registration first within each.

• Reducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving BirthCompletedNCT00109590Phase 2Results posted
• Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation PatientsCompletedNCT00105235Phase 2Results posted
• Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic PolyangiitisCompletedNCT00104299Phase 2/3Results posted
• Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at BirthCompletedNCT00102960Phase 3Results posted
• Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During PregnancyCompletedNCT00099632Phase 2Results posted
• Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple SclerosisCompletedNCT00094172Phase 2Results posted
• Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected PatientsCompletedNCT00085917Phase 2Results posted
• Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIVCompletedNCT00084149Phase 2Results posted
• Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)CompletedNCT00078403Phase 2Results posted
• Preventing Sexual Transmission of HIV With Anti-HIV DrugsCompletedNCT00074581Phase 3Results posted
• Using Nevirapine to Prevent Mother-to-Child HIV Transmission During BreastfeedingCompletedNCT00074412Phase 3Results posted
• Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral TxCompletedNCT00071890Phase 2Results posted
• Interferon-beta1a (AVONEX) Treatment of Ulcerative ColitisCompletedNCT00048347Phase 2Results posted
• Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After PregnancyCompletedNCT00042289Results posted
• Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected ChildrenCompletedNCT00039741Phase 2/3Results posted
• Long Term Treatment of Herpes Simplex Encephalitis (HSE) With ValacyclovirCompletedNCT00031486Phase 3Results posted
• Acyclovir for Herpes Infections Involving the Central Nervous System in NeonatesCompletedNCT00031460Phase 3Results posted
• Acyclovir Herpes Simplex Virus (HSV) Skin, Eye, and MouthCompletedNCT00031447Phase 3Results posted
• Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic VasculitisCompletedNCT00029107Phase 2Results posted
• Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected PatientsCompletedNCT00018031Phase 2Results posted
• Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV DrugsCompletedNCT00016718Phase 1/2Results posted
• Islet Transplantation for Type 1 DiabetesCompletedNCT00014911Phase 2Results posted
• Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and AdolescentsCompletedNCT00006604Phase 1/2Results posted
• An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral TherapyCompletedNCT00004978Phase 3Results posted
• A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular RoutesActive, not recruitingNCT07221162Phase 1
• L9LS-R21 InteractionWithdrawnNCT07208760Phase 2
• Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in AdultsActive, not recruitingNCT07183709Phase 1
• Improving Physical Ability and Cellular Senescence Elimination in HIVCompletedNCT07144293Phase 2
• Safety, Reactogenicity, and Immunogenicity Trial of STX-S SARS-CoV-2 Vaccine in AdultsCompletedNCT07095231Phase 1
• L9LS in Women of Childbearing Potential in MaliCompletedNCT07060508Phase 2
• A Study to Evaluate the Safety and Immunogenicity of Two Doses of a Novel H5 Central Antigen mRNA-LNP in Healthy AdultsCompletedNCT07019883Phase 1
• A Study to Evaluate the Safety and Immunogenicity of the V3-region Directed Immunogens DV700P-RNA Followed by DV701B1.1-RNA in Adults Without HIVActive, not recruitingNCT06919016Phase 1
• A Clinical Trial to Evaluate the Safety and Immunogenicity of Glycan-trimmed HIV-1 Nanoparticle Vaccine (UVAX-1107), Followed by Homologous or Wild-type HIV-1 Nanoparticle Vaccine (UVAX-1197) Boost, Each Adjuvanted With 3M-052-AF + Alum in Adult Participants Without HIVSuspendedNCT06905275Phase 1
• Study of the Esophageal String Test (EST) for the Diagnosis of Helicobacter PyloriCompletedNCT06871579Not applicable
• Safety and Challenge Study of BCG TICE(R) Vaccination to Test Tuberculosis Immunity in Heathy HumansWithdrawnNCT06845358Phase 1
• A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIVActive, not recruitingNCT06812494Phase 2
• Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP ChallengeCompletedNCT06805487Phase 1
• Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine in Healthy AdultsActive, not recruitingNCT06745921Phase 1
• First-in-Human PfSPZ-LARC2 Vaccination/CHMICompletedNCT06735209Phase 1
• Tecovirimat for Treatment of Monkeypox Virus - Study Extension Providing Standard of Care OnlyCompletedNCT06721585
• Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI)CompletedNCT06709521Phase 4
• Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIVSuspendedNCT06705478Phase 2
• Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy AdultsCompletedNCT06692907Phase 2
• Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral TherapySuspendedNCT06680479Phase 1
• Study of a Human Bispecific Antibody VRC-HIVMAB0121-00-AB (CAP256J3LS) Administered Intravenously or Subcutaneously to Healthy AdultsCompletedNCT06585891Phase 1
• CROSSOVER STUDY OF ON-DEMAND PREP FORMULATIONS COMPARING RECTAL AND ORAL TENOFOVIRCompletedNCT06560684Phase 2
• A Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by CH505 TF mRNA-gp160 in Adults in Overall Good Health Without HIVActive, not recruitingNCT06557785Phase 1
• The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both ProductsCompletedNCT06551506Phase 4
• The Tatelo Plus StudyActive, not recruitingNCT06508749Phase 1/2
• Safety and Immunogenicity Trial of MPV/S-2P SARS-CoV-2 Vaccine in AdultsCompletedNCT06441968Phase 1
• CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in PregnancyWithdrawnNCT06336434Phase 1/2
• Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV.Active, not recruitingNCT06332339Phase 1
• A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + AlumWithdrawnNCT06267872Phase 1
• Investigation of Immune Amnesia Following Measles Infection in Select African RegionsCompletedNCT06153979
• A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital CytomegalovirusCompletedNCT06118515Phase 1
• Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1SuspendedNCT06071767Phase 1/2
• A Trial to Evaluate an HIV Envelope Trimer, N332-GT5 gp140, Adjuvanted With SMNP in Adult Participants Without HIVCompletedNCT06033209Phase 1
• Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in AdultsCompletedNCT06026514Phase 1
• The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage AntibodiesActive, not recruitingNCT06006546Phase 1
• Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy AdultsCompletedNCT05968989Phase 1
• A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy AdultsCompletedNCT05945485Phase 1
• Study of the Plasmodium Vivax Transmission-blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogenicity, and Transmission-blocking Activity in Healthy Malaria-naive AdultsCompletedNCT05913973Phase 1
• Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIVActive, not recruitingNCT05903339Phase 1
• To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIVCompletedNCT05854381Phase 1
• A Study of Doxycycline to Treat Chlamydial InfectionCompletedNCT05840159Phase 4
• A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy AdultsCompletedNCT05755620Phase 1
• Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative PersonsCompletedNCT05683834Phase 1/2
• Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1)WithdrawnNCT05652504Phase 1
• The Role of Gut Microbiome in Predicting Comorbidities and Complications in Children With Inflammatory Bowel DiseaseWithdrawnNCT05652491
• A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral TherapyActive, not recruitingNCT05612178Phase 1
• Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)Active, not recruitingNCT05600907Early Phase 1
• Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant TuberculosisCompletedNCT05586230Phase 1
• A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 InfectionWithdrawnNCT05582694Phase 2
• Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIVCompletedNCT05551273Phase 2
• Natural History, Disease Progression, and Long-Term Neurologic Sequelae of Ebola Virus Disease (EVD) Survivors in PREVAIL IIICompletedNCT05494801
• Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b and Optional Boost Regimen With HIV Trimer BG505 SOSIP.GT1.1 gp140, Both Adjuvanted With 3M-052-AF + Alum in Healthy, Adult Participants Without HIVCompletedNCT05471076Phase 1
• Low Pathogenicity Avian H10N7 Influenza Virus in a Healthy Human Challenge ModelCompletedNCT05436444Phase 1
• Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and AdolescentsActive, not recruitingNCT05347771Phase 2
• Ocrelizumab Discontinuation in Relapsing Multiple SclerosisActive, not recruitingNCT05285891Phase 4
• Safety and Efficacy of Tofacitinib for Chronic Granulomatous Disease With Inflammatory ComplicationsCompletedNCT05104723Phase 1/2
• International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE)CompletedNCT05096091
• Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATIWithdrawnNCT05079451Phase 1
• Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious DiseasesActive, not recruitingNCT05078905
• Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 DeficiencyCompletedNCT05078879Phase 1
• Carfilzomib and Belatacept for DesensitizationActive, not recruitingNCT05017545Phase 1/2
• Community Dynamics of Malaria Transmission in Humans and Mosquitoes at Maferinyah Sub-Prefecture, GuineaCompletedNCT04969913
• Natural History of Systemic and Nasal Mucosal Immunity After Influenza Vaccination in a Pediatric PopulationCompletedNCT04963166
• PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in LiberiaCompletedNCT04926922
• Selective CD28 Blockade in Renal Transplant RecipientsWithdrawnNCT04903054Phase 2
• Daratumumab and Belatacept for DesensitizationCompletedNCT04827979Phase 1/2
• The Effect of Helminth Infection Plus COVID-19 Infection on the Immune Response and Intestinal MicroorganismsActive, not recruitingNCT04813328
• Safety and Survival of Genetically Modified White Blood Cells in HIV-infected Twins The Gemini StudyActive, not recruitingNCT04799483
• Systems Biology of Early AtopyActive, not recruitingNCT04798079
• Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After VaccinationCompletedNCT04794829
• Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, LiberiaActive, not recruitingNCT04704674
• Malaria Transmission in Humans and Mosquitoes at the Area of Sabou, Burkina FasoCompletedNCT04650815
• SARS-COV2 Pandemic Serosurvey in a Rare Disease PopulationCompletedNCT04609085
• Defining the COVID-19 Immunity Denominator in the Mekong: a Cross-Sectional Seroprevalence Study of SARS-CoV-2 in HealthyVolunteersWithdrawnNCT04594395
• COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-CCompletedNCT04588363
• The Influence of Malnutrition, Diabetes Mellitus, and Helminth Infections on Biosignatures in Latent Tuberculosis in a South Indian PopulationCompletedNCT04526613

← National Institute of Allergy and Infectious Diseases (NIAID) overview and focus areas